These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30821530)

  • 1. Exciting advances in GPCR-based drugs discovery for treating metabolic disease and future perspectives.
    Quiñones M; Fernø J; Diéguez C; Nogueiras R; Al-Massadi O
    Expert Opin Drug Discov; 2019 May; 14(5):421-431. PubMed ID: 30821530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
    Baggio LL; Drucker DJ
    Mol Metab; 2021 Apr; 46():101090. PubMed ID: 32987188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of novel ligands for peptide GPCRs.
    Moran BM; McKillop AM; O'Harte FP
    Curr Opin Pharmacol; 2016 Dec; 31():57-62. PubMed ID: 27607913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Class B1 GPCRs: insights into multireceptor pharmacology for the treatment of metabolic disease.
    Sangwung P; Ho JD; Siddall T; Lin J; Tomas A; Jones B; Sloop KW
    Am J Physiol Endocrinol Metab; 2024 Nov; 327(5):E600-E615. PubMed ID: 38984948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GLP-1/glucagon receptor co-agonism for treatment of obesity.
    Sánchez-Garrido MA; Brandt SJ; Clemmensen C; Müller TD; DiMarchi RD; Tschöp MH
    Diabetologia; 2017 Oct; 60(10):1851-1861. PubMed ID: 28733905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel approaches to anti-obesity drug discovery with gut hormones over the past 10 years.
    Rose F; Bloom S; Tan T
    Expert Opin Drug Discov; 2019 Nov; 14(11):1151-1159. PubMed ID: 31355685
    [No Abstract]   [Full Text] [Related]  

  • 8. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
    Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
    Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists.
    Finan B; Clemmensen C; Müller TD
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():42-54. PubMed ID: 26151488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing Poly-agonists for Treatment of Metabolic Diseases: Challenges and Opportunities.
    Petersen J; Strømgaard K; Frølund B; Clemmensen C
    Drugs; 2019 Jul; 79(11):1187-1197. PubMed ID: 31243696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. G protein-coupled receptors driven intestinal glucagon-like peptide-1 reprogramming for obesity: Hope or hype?
    Patil M; Casari I; Warne LN; Falasca M
    Biomed Pharmacother; 2024 Mar; 172():116245. PubMed ID: 38340396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
    Finan B; Ma T; Ottaway N; Müller TD; Habegger KM; Heppner KM; Kirchner H; Holland J; Hembree J; Raver C; Lockie SH; Smiley DL; Gelfanov V; Yang B; Hofmann S; Bruemmer D; Drucker DJ; Pfluger PT; Perez-Tilve D; Gidda J; Vignati L; Zhang L; Hauptman JB; Lau M; Brecheisen M; Uhles S; Riboulet W; Hainaut E; Sebokova E; Conde-Knape K; Konkar A; DiMarchi RD; Tschöp MH
    Sci Transl Med; 2013 Oct; 5(209):209ra151. PubMed ID: 24174327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Incretin-based co- and tri-agonists : Innovative polypharmacology for the treatment of obesity and diabetes].
    Harger A; Stemmer K; Tschöp MH; Müller TD
    Internist (Berl); 2019 Sep; 60(9):895-902. PubMed ID: 31346639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational glucagon-like peptide-1 agonists for the treatment of obesity.
    Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1167-79. PubMed ID: 27563838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The therapeutic potential of GPR119 agonists for type 2 diabetes.
    Ohishi T; Yoshida S
    Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism.
    Hansen MSS; Tencerova M; Frølich J; Kassem M; Frost M
    Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):25-37. PubMed ID: 28722834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity.
    Lin CH; Shao L; Zhang YM; Tu YJ; Zhang Y; Tomlinson B; Chan P; Liu Z
    Expert Opin Pharmacother; 2020 Feb; 21(3):275-285. PubMed ID: 31790314
    [No Abstract]   [Full Text] [Related]  

  • 18. Biological characteristics and agonists of GPR120 (FFAR4) receptor: the present status of research.
    Li A; Li Y; Du L
    Future Med Chem; 2015; 7(11):1457-68. PubMed ID: 26230883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.